Results 61 to 70 of about 4,490 (182)

Asymmetric Synthesis of Tertiary α‐Aryl Stereocentres in Tetrahydro‐4H‐pyran‐4‐ones Using Pd‐Catalyzed Decarboxylative Asymmetric Protonation

European Journal of Organic Chemistry, Volume 29, Issue 36, 24 September 2026.
The Pd‐catalyzed decarboxylative asymmetric protonation (DAP) has been developed for sterically hindered tetrahydro‐4H‐pyran‐4‐one derived α‐aryl‐β‐keto esters. A substrate scope of nine examples of DAP showed that substrates containing a di‐ortho methoxy substitution pattern on the aryl ring gave rise to the highest enantioselectivities of up to 85 ...
Fionn McNeill, Joffrey Scriven, Fritz Bahns, Anugam V. Krishna, Julia Bruno‐Colmenarez, Patrick J. Guiry   +5 more
wiley   +1 more source

Entrectinib in the neoadjuvant setting of anaplastic thyroid cancer: a case report [PDF]

, 2022
BACKGROUND: Anaplastic thyroid carcinoma (ATC) is one of the most aggressive solid tumors. ATC is frequently diagnosed at advanced stages with unresectable disease and palliative care is often indicated.
Rito, Miguel, Simões-Pereira, Joana, Horta, Mariana, Damásio, Inês, Donato, Sara, Gomes, Pedro, Leite, Valeriano, Cavaco, Branca Maria   +7 more
core   +1 more source

Entrectinib Response to ROS1-Fusion-Positive Non-Small-Cell Lung Cancer That Progressed on Crizotinib with Leptomeningeal Metastasis: A Case Report

Case Reports in Oncology, 2023
Introduction: C-ros oncogene 1 (ROS1) translocation is an oncogenic driver-mutation identified in 1–2% of non-small-cell lung cancer (NSCLC) cases. Although crizotinib, a tyrosine kinase inhibitor (TKI) against ALK/ROS1, is known to be effective against ...
Hiromune Sawada, Yuri Taniguchi, Shin Iizuka, Toshiki Ikeda, Masaharu Aga, Yusuke Hamakawa, Kazuhito Miyazaki, Yuki Misumi, Yoko Agemi, Yukiko Nakamura, Koki Maeda, Tsuneo Shimokawa, Hiroaki Okamoto   +12 more
doaj   +1 more source

Substituent Effects of Heptamethine Cyanine Dyes on Drug Uptake in Patient‐Derived Glioma Cells

ChemMedChem, Volume 21, Issue 17, 14 September 2026.
Glioblastoma (GBM) remains difficult to treat primarily due to tumor heterogeneity and the presence of the blood–brain barrier (BBB). This study demonstrates the in vitro activity of the pan‐kinase inhibitor crizotinib conjugated to BBB‐penetrating heptamethine cyanine dyes with diverse functional groups across four patient‐derived GBM cell lines ...
Carina J. Dumo, Peter J. Choi, Yuge Liu, Osaid Muhammad, Jason A. Correia, Mike Dragunow, Thomas I‐H. Park, Jiney Jose   +7 more
wiley   +1 more source

From genomic spectrum of NTRK genes to adverse effects of its inhibitors, a comprehensive genome-based and real-world pharmacovigilance analysis

Frontiers in Pharmacology
Introduction: The discovery of neurotrophic tyrosine receptor kinase (NTRK) gene fusions has facilitated the development of precision oncology. Two first-generation NTRK inhibitors (larotrectinib and entrectinib) are currently approved for the treatment ...
Zhiwei Cui, Zhen Zhai, De Xie, Lihui Wang, Feiyan Cheng, Siyu Lou, Fan Zou, Rumeng Pan, Shixue Chang, Haoyan Yao, Jing She, Yidan Zhang, Xinyuan Yang   +12 more
doaj   +1 more source

Not all NTRK fusions in mesenchymal neoplasia are driver events: implications on classification and targeted therapy

The Journal of Pathology: Clinical Research, Volume 12, Issue 5, September 2026.
Abstract NTRK fusions drive the pathogenesis of a distinctive group of mesenchymal neoplasms with significant impact on classification and targeted therapy. However, unexpected NTRK fusions have been reported in other sarcoma entities, raising uncertainty over their specificity and clinical management.
Mohamed A Yakoub, Purvil Sukhadia, Carla Saoud, Meera Hameed, Cristina R Antonescu   +4 more
wiley   +1 more source

Entrectinib can induce nerve cell damage by inhibiting PI3K-AKT and TGF-β signaling pathways

Frontiers in Pharmacology
BackgroundThe tyrosine receptor kinase inhibitor (TRKi) entrectinib is used to treat neurotrophic tyrosine receptor kinase (NTRK) fusion-positive solid tumors and ROS1-positive patients.
Qingshan Tang, Jiachen Dong, Feng Zhang, Dan Zhao, Qi Yang, Jiayu Wen, Yuhao Sun, Jifu Wei, Zhixian Liu   +8 more
doaj   +1 more source

An Integrative Strategy Delineates Modular Metabolic Remodeling and Potential Therapeutic Targets Across Metabolic Diseases

Advanced Science, Volume 13, Issue 52, 18 September 2026.
An integrative single‐cell atlas across multiple metabolic diseases reveals coordinated metabolic modules and disease‐shared versus disease‐specific pathway activities. By systematically comparing scoring strategies, a robust RankAve framework is established. Coupled with network analysis and drug‐target prediction, this resource uncovers cross‐disease
Kuan Yang, Congxue Hu, Hang Zhao, Xiao Peng, Yiming Yan, Jiasi Wang, Wenqi Jiang, Depeng Mu, Yan Cao, Xia Li, Yunpeng Zhang   +10 more
wiley   +1 more source

Immunological Features of Neuroendocrine Neoplasms and Adrenal Tumors

Cancer Medicine, Volume 15, Issue 9, September 2026.
ABSTRACT Neuroendocrine neoplasms, which occur throughout the human body, as well as adrenocortical carcinoma and pheochromocytoma, which originate in the adrenal gland, are primarily classified as rare malignancies. Immunotherapy, including immune checkpoint inhibitors (ICIs), is generally not incorporated into the standard care protocols for these ...
Akihiro Ohmoto, Shunji Takahashi, Shigehisa Kitano   +2 more
wiley   +1 more source

A case of lung adenocarcinoma with a novel CD74‐ROS1 fusion variant identified by comprehensive genomic profiling that responded to crizotinib and entrectinib

Thoracic Cancer, 2021
ROS1 rearrangements are found in 1–2% of patients with non‐small‐cell lung cancer. The detection of the rearrangements is crucial since clinically effective molecular targeted drugs are available for them.
Mizuha Haraguchi Hashiguchi, Takashi Sato, Rinako Watanabe, Junko Kagyo, Tomohiko Matsuzaki, Hideharu Domoto, Terufumi Kato, Yoshiro Nakahara, Tomoyuki Yokose, Yukihiko Hiroshima, Tetsuya Shiomi   +10 more
doaj   +1 more source